PharmAla Biotech licenses exclusive US rights to ALA-002 to Jupiter Neurosciences for up to US$100 million

Reuters2026/07/21 11:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pharmala Biotech granted Jupiter Neurosciences an exclusive, perpetual, royalty-bearing license for U.S. development and commercialization of ALA-002.
Total consideration up to about USD 100 million, including USD 3.33 million upfront, paid in cash and Jupiter common stock.
Contingent milestones up to USD 96.67 million tied to development, FDA approval, and U.S. net sales thresholds.
Royalty set at 3% of U.S. net sales, starting after the third commercialization milestone.
Pharmala retains ALA-002 rights outside the U.S., committing to supply GMP-grade drug product under a separate supply agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210700PRIMZONEFULLFEED9765029) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PharmAla Biotech licenses exclusive US rights to ALA-002 to Jupiter Neurosciences for up to US$100 million

You may also like

Crypto prices